| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT03988114 2019-001781-16 Details | 2019-09-06 Interventional | 4 | 0 | Aromatase Inhib… Breast Neoplasm… Metastatic Brea… | Strategic decision due to emerging new data for patients with HR+, HER2- metastatic breast
cancer. - | |||
| NCT02902809 Details | 2019-09-06 Interventional | 3 | 28 | Antibodies, Mon… Asthma Inadequately Co… | The study was terminated due to the discontinuation of the tralokinumab asthma program (as per
the results of the Phase III study [D2210C00008]) Study was terminated due to discontinuation of tralokinumab asthma program. Study was reported in a synopsis format. Individual listings of laboratory variables, physical examinations, vitals and ECG were evaluated for safety signal. | |||
| NCT02789189 Details | 2019-09-06 Interventional | 2 | - | Gemcitabine Nedaplatin Carcinoma Nasopharyngeal … Recurrent and M… | - - | |||
| NCT02674893 Details | 2019-09-06 Interventional | 4 | 48 | Liraglutide Diabetes Mellit… Diabetes Mellit… Overweight Type 2 Diabetes | Exploratory protocol, convincing results, robust analysis - | |||
| NCT02302339 Details | 2019-09-06 Interventional | 2 | 132 | Antibodies, Mon… Glembatumumab v… Nivolumab Pembrolizumab Melanoma | Development of glembatumumab vedotin was discontinued Study was discontinued early, leading to small number of subjects analyzed in Cohort 4 and minimal patient follow up in Cohorts 3 and 4. | |||
| NCT01679405 Details | 2019-09-06 Interventional | 1 | 9 | Afatinib Cisplatin Gemcitabine Neoplasm Metast… Metastatic Dise… | No sufficient clinical or molecular signals for efficacy were observed. - | |||
| NCT01408160 Details | 2019-09-06 Interventional | 1 | 18 | Cytarabine Immunotoxins Leukemia Leukemia, Lymph… Precursor Cell … Adult B Acute L… Recurrent Adult… | - - | |||
| NCT01335867 Details | 2019-09-06 Interventional | 2 | 32 | Vigabatrin Alcoholism Cocaine-Related… Cocaine Depende… | interim analysis of efficacy completed and termination recommended - | |||
| NCT01938664 Details | 2019-09-04 Interventional | 2 | 30 | Candesartan Candesartan cil… Cocaine-Related… Cocaine Depende… | Results of interim efficacy analysis showed results were not promising. - | |||
| NCT01182350 Details | 2019-09-04 Interventional | 2 | [1 Refs] | 53 | Bevacizumab Erlotinib Hydro… Temozolomide Diffuse Intrins… Glioma | Per design: Stop if fewer than 3 cohorts by molecular classification were with 10 participants
or only 1 cohort enrolled at least 15 participants of 50. The study was terminated early having met the pre-specified stopping rule which required 3 or more cohorts with at least 10 patients each or 2 cohorts with at least 15 patients each in the first 50 patients with informative biopsies. | ||
| NCT02614508 Details | 2019-09-03 Interventional | 1 | 1 | Antibodies, Mon… Ibrutinib Ofatumumab Leukemia Leukemia, Lymph… Leukemia, Lymph… Lymphoma Recurrence Recurrent Chron… Recurrent Small… Refractory Chro… Refractory Smal… | - - | |||
| NCT01648465 2011-006160-48 Details | 2019-09-03 Interventional | 2 | 25 | Everolimus Digestive Syste… Gastrointestina… Intestinal Neop… Neoplasms Neuroendocrine … Pancreatic Neop… Stomach Neoplas… Gastrointestina… Gastrointestina… Pancreatic Neur… Pancreatic Tumo… | - - | |||
| NCT02982395 Details | 2019-08-30 Interventional | 3 | 36 | Docetaxel Ethanol Mitomycin Mitomycins Non-Muscle Inva… Urinary Bladder… Non Muscle Inva… | - - | |||
| NCT02972450 Details | 2019-08-29 Interventional | 1/2 | 1 | Vaccines Vedolizumab Communicable Di… Infections Persistent Infe… HIV-1-infection | Due to the bankruptcy of FITBiotech, the provider of the GTU DNA vaccine. - | |||
| NCT03785184 Details | 2019-08-28 Interventional | 2 | 0 | Dexamethasone Lenalidomide Venetoclax Multiple Myelom… Neoplasms, Plas… | Strategic considerations - | |||
| NCT03602118 Details | 2019-08-28 Interventional | 3 | 0 | Phenobarbital Seizures Neonatal Seizur… | Sponsor withdrawing the subject IND - | |||
| NCT03582007 Details | 2019-08-28 Interventional | 3 | 2 | Anti-Bacterial … Murepavadin Healthcare-Asso… Pneumonia | Safety data review - | |||
| NCT03409679 Details | 2019-08-28 Interventional | 3 | 41 | Anti-Bacterial … Murepavadin Pneumonia | Safety data review - | |||
| NCT03407404 Details | 2019-08-28 Interventional | 2/3 | 124 | Ketamine Midazolam Morphine Critical Illnes… | Futility - | |||
| NCT02918708 Details | 2019-08-28 Interventional | 4 | 0 | Heptavalent Pne… Immunization Vaccination | funding channel amended by UK department of health - |